Tavapadon (Juvmo, AbbVie) is the first and only selective D1/D5 dopamine receptor agonist for adults with Parkinson’s disease, marking the first new dopaminergic treatment approach for the PD in decades. Approval was based on the Phase 3 TEMPO clinical trial program, which demonstrated significant improvements in motor symptoms, daily functioning, and increased “on” time without troublesome dyskinesia in patients with Parkinson’s disease. Tavapadon selectively targets D1/D5 receptors and offers a once-daily treatment option that can be used with or without levodopa therapy.